AU2001254885A1 - Modified ES cells and ES cell-specific gene - Google Patents

Modified ES cells and ES cell-specific gene

Info

Publication number
AU2001254885A1
AU2001254885A1 AU2001254885A AU2001254885A AU2001254885A1 AU 2001254885 A1 AU2001254885 A1 AU 2001254885A1 AU 2001254885 A AU2001254885 A AU 2001254885A AU 2001254885 A AU2001254885 A AU 2001254885A AU 2001254885 A1 AU2001254885 A1 AU 2001254885A1
Authority
AU
Australia
Prior art keywords
cells
modified
cell
specific gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001254885A
Other versions
AU2001254885B2 (en
Inventor
Herve Acloque
Anne-Marie Birot
Bertrand Pain
Valerie Risson
Jacques Samarut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Recherche Agronomique INRA
Ecole Normale Superieure de Lyon
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Recherche Agronomique INRA
Ecole Normale Superieure de Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0006029A external-priority patent/FR2808803B1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Recherche Agronomique INRA, Ecole Normale Superieure de Lyon filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2001254885A1 publication Critical patent/AU2001254885A1/en
Application granted granted Critical
Publication of AU2001254885B2 publication Critical patent/AU2001254885B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001254885A 2000-05-11 2001-04-19 Modified es cells and es cell-specific gene Ceased AU2001254885B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0006029 2000-05-11
FR0006029A FR2808803B1 (en) 2000-05-11 2000-05-11 MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS
PCT/FR2001/001207 WO2001085938A1 (en) 2000-05-11 2001-04-19 Modified es cells and es cell-specific gene

Publications (2)

Publication Number Publication Date
AU2001254885A1 true AU2001254885A1 (en) 2002-02-07
AU2001254885B2 AU2001254885B2 (en) 2006-08-10

Family

ID=8850125

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001254885A Ceased AU2001254885B2 (en) 2000-05-11 2001-04-19 Modified es cells and es cell-specific gene
AU5488501A Pending AU5488501A (en) 2000-05-11 2001-04-19 Modified es cells and es cell-specific gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5488501A Pending AU5488501A (en) 2000-05-11 2001-04-19 Modified es cells and es cell-specific gene

Country Status (14)

Country Link
US (2) US20040072169A1 (en)
EP (1) EP1280898B1 (en)
JP (1) JP2004515212A (en)
AT (1) ATE498011T1 (en)
AU (2) AU2001254885B2 (en)
BR (1) BR0110764A (en)
CA (1) CA2408732A1 (en)
DE (1) DE60144015D1 (en)
DK (1) DK1280898T3 (en)
ES (1) ES2358731T3 (en)
FR (1) FR2808803B1 (en)
NO (1) NO331814B1 (en)
NZ (1) NZ522547A (en)
WO (1) WO2001085938A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808803B1 (en) * 2000-05-11 2004-12-10 Agronomique Inst Nat Rech MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS
WO2002097090A1 (en) * 2001-05-31 2002-12-05 Sumitomo Pharmaceuticals Co., Ltd. Genes with es cell-specific expression
CN101365480B (en) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US20090220541A1 (en) 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
JP2009514850A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
DK2368572T3 (en) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvant vaccines with non-virion antigens produced from influenza viruses grown in cell culture
PT1951299E (en) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EP2478916B1 (en) 2006-01-27 2020-04-01 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
FR2898909A1 (en) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combination of markers to characterize avian cells of StX cells, germinal cells or stem cells, comprises markers of a target gene expressed in the StX cells, stem cells or in the germinal cells
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CN101553252A (en) 2006-12-06 2009-10-07 诺华有限公司 Vaccines including antigen from four strains of influenza virus
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
JP5843615B2 (en) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Purification of viruses or viral antigens by density gradient ultracentrifugation
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
FR2949344A1 (en) 2009-04-27 2011-03-04 Novartis Ag FLU PROTECTIVE VACCINES
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EP2545172B2 (en) 2010-03-08 2017-12-06 Novartis AG Methods of testing for intracellular pathogens
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
KR20130079398A (en) 2010-05-06 2013-07-10 노파르티스 아게 Organic peroxide compounds for microorganism inactivation
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
KR20130081659A (en) 2010-06-01 2013-07-17 노파르티스 아게 Concentration of vaccine antigens with lyophilization
PT2575872T (en) 2010-06-01 2020-11-19 Seqirus Uk Ltd Concentration of influenza vaccine antigens without lyophilization
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
BE1022132B1 (en) 2013-08-30 2016-02-19 Glaxosmithkline Biologicals S.A. NEW METHOD.
ES2721535T3 (en) 2014-12-16 2019-08-01 Glaxosmithkline Biologicals Sa Large-scale virus purification procedure
PT3233130T (en) 2014-12-17 2021-06-24 Fundacion Para La Investig Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
PT3233129T (en) 2014-12-17 2020-04-15 Fundacion Para La Investig Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
EP3794127A1 (en) 2018-05-14 2021-03-24 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
MX2021004154A (en) 2018-10-12 2021-08-05 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3).
CA3118936A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
CA3145446A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
CN115380107A (en) 2019-11-18 2022-11-22 思齐乐私人有限公司 Method for producing reassortant influenza viruses
CA3181024A1 (en) 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
PE20230987A1 (en) 2020-10-09 2023-06-21 UCB Biopharma SRL NUCLEIC ACID CONSTRUCTS, VIRAL VECTORS AND VIRAL PARTICLES
AU2022378524A1 (en) 2021-10-28 2024-05-02 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309822B1 (en) * 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
FR2726003B1 (en) * 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
CA2341754A1 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
FR2808803B1 (en) * 2000-05-11 2004-12-10 Agronomique Inst Nat Rech MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS

Similar Documents

Publication Publication Date Title
AU2001254885A1 (en) Modified ES cells and ES cell-specific gene
AU2001253077A1 (en) Electrochemical cell and assembly for same
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU1201600A (en) Controlling gene expression in living cells
AU2126502A (en) Gene expression profiles in granulocytic cells
EP1333086A4 (en) Cell culture case
AU2002306374A1 (en) Genes with ES cell-specific expression
AU2001250036A1 (en) Microdroplet cell culture technique
AU2001235452A1 (en) Cell culture media
AU2002325758A1 (en) Cultured stromal cells and uses thereof
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU2001267724A1 (en) Electrochemical cell
AU2001270478A1 (en) Gene expression in biological conditions
AU2001275897A1 (en) Improvement of cell culture performance
AU2295201A (en) Spore-like cells and uses thereof
AU2001269081A1 (en) Electrochemical cells
AU4771600A (en) Cells, culture methods and their uses
AU2002232032A1 (en) Electrochemical cells and their packaging
AU2153401A (en) Gene expression in biological conditions
AU2001247444A1 (en) Erbeta-mediated gene expression
AU1894601A (en) Novel gene and use thereof
AU2001254976A1 (en) Electrochemical methods and cells
AU5545700A (en) Dna manipulation methods and applications for synthetic enzymes
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2002246758A1 (en) Epididymal lipocalin gene and uses thereof